{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5096, 
        5103
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5480, 
        5487
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4983, 
        4992
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5104, 
        5113
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5488, 
        5497
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7376, 
        7396
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7398, 
        7406
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4836, 
        4863
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4865, 
        4875
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5043, 
        5047
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5338, 
        5342
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7286, 
        7287
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7302, 
        7303
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7318, 
        7319
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7334, 
        7335
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7350, 
        7351
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7280, 
        7282
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7296, 
        7298
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7312, 
        7314
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7328, 
        7330
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7344, 
        7346
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        546, 
        575
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        577, 
        594
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3683, 
        3718
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3720, 
        3732
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7224, 
        7250
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7252, 
        7270
      ]
    }
  ], 
  "Negative Findings Phraseology (Ov)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4150, 
        4183
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4959, 
        4992
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4972, 
        4982
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5471, 
        5479
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5661, 
        5662
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5048, 
        5054
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7360, 
        7366
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5358, 
        5378
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5389, 
        5398
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Gemma", 
      "__extent": [
        4875, 
        4882
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5040, 
        5042
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7272, 
        7279
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7288, 
        7295
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7304, 
        7311
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7320, 
        7327
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7336, 
        7343
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7352, 
        7359
      ]
    }
  ], 
  "__text": "MSH|^~\\&|LABCORP-CORP|LABCORP^34D0655059^CLIA|Cancer Registry|State|201706010938|State006|ORU^R01|2017060107093839521000|P|2.3.1\nPID|1||^^^^SS^~11111111^^^^PI^|ALTERNATE ID|TEST^PATIENT^A||19500601|M||2054-5^Black or African American^CDC^^^|1234 Test Road^^ALBANY^NY^12201||^^^^^222^1234567|||||||\nORC|RE||111A1111111||||||||||||||||||Ordering Facility Name^^L|2222 W. Test Road^^Test^TX^77025|^^^^^111^1234567||\nOBR|1||111A1111111|^^^111111^Pathology Report^L|||201705301335|||||||20090115||Ordering Provider Name||||||20170530|||F|||||||\n\n\n\n\n\n\nPath report.gross observation\n\nGross description: The specimens are received in formalin, labeled with the patient's name and sublabeled as the following: (1) SN #1 left; (2) SN #2 left; (3) SN #3 left; (4) left sentinel node #4; (5) left sentinel node #5; (6) left breast. \n (1) The specimen was previously received unfixed for frozen section  performed at Edmonds Center for Outpatient Surgery and consists of  a piece of adipose tissue (2.2 x 1.4 x 0.5 cm). Section code: (A1)  remaining tissue for frozen section; (A2) remaining tissue. Specimen  entirely submitted. (2) The specimen was previously received unfixed for frozen section  performed at Edmonds Center for Outpatient Surgery and consists of  a piece of adipose tissue (2.5 x 2.5 x 0.8 cm). Section code:  (B1-B2) remaining tissue for frozen section; (B3) remaining tissue.  Specimen entirely submitted. (3) The specimen was previously received unfixed for frozen section  performed at Edmonds Center for Outpatient Surgery and consists of  a piece of adipose tissue (2.0 x 1.0 x 0.5 cm). Section code:  (C1) remaining tissue for frozen section; (C2) remaining tissue.  Specimen entirely submitted. (4) The specimen was previously received unfixed for frozen section  performed at Edmonds Center for Outpatient Surgery and consists of  a piece of adipose tissue (1.5 x 1.5 x 0.5 cm). Section code:  (D1) remaining tissue for frozen section; (D2) remaining tissue.  Specimen entirely submitted. (5) The specimen was previously received unfixed for frozen section  performed at Edmonds Center for Outpatient Surgery and consists of  a piece of adipose tissue (1.0 x 1.0 x 0.8 cm). Section code:  (E1) remaining tissue for frozen section; (E2) remaining tissue.  Specimen entirely submitted. (6) The specimen consists of an inked and sliced piece of breast  tissue (2.7 cm AP, 5.0 cm ML, 4.2 cm SI) with no overlying skin.  One localization wire enters the medial aspect and exits the  inferomedial aspect. The specimen is received sliced into 12 slices.  One mass (slice 3) is approximately 1 cm or greater from inked  margins. Second possible mass (slice 5) is 4 mm from black-superior  margin. The remaining tissue is densely fibrous with no other nodules,  masses or lesions identified. A biopsy marker is located in slice  #4. Ink code: purple-anterior;yellow-posterior; black-superior;  orange-inferior; green-medial; blue-lateral. Section code: (F1-F3)  slice #1, perpendicularly sectioned; (F4-F7) slice #2, quartered;  (F8-F11) slice #3, quartered; (F12-F15, F16-F19) slice #4, spliced,  each splice is quartered; (F20-F23, F24-F27) slice #5, spliced, each  splice is quartered; (F28) slice #6; (F29) slice #7; (F30) slice #8;  (F31) slice #9; (F32) slice #10; (F33) slice #11; (F34) slice #12,  perpendicularly sectioned. Specimen entirely submitted.  Note: Approximate total fixation time in formalin-29 hours 30 minutes,  calculated using a collection date of 07/25/2017 with a time in  formalin of 13:44. (JM:cmc10 717525) /MRV\n\n\nPayment procedure\n\nCPT                            .883071, 883072, 883073, 883074, 883075, 883076, 883315, 883291, W20074, W20534\n\n\nPath report.microscopic observation\n\nMicroscopic: Immunohistochemical stains were performed to characterize the cells of interest. Control stains showed appropriate reactivity. \n Results: A1, B1-B2, C1, D1, E1: OSCAR: Negative F2, F4, F8, F23, F25, F32:  P63 highlights myoepithelial cells.  E-cadherin is negative in intraluminal cells. F5: P63 highlights myoepithelial cells. F18: E-cadherin is negative in the invasive carcinoma. \n Interpretation: Lymph nodes are negative for metastatic carcinoma by IHC. Ecadherin is negative in the invasive carcinoma and in the in situ component. p63 aids in clarifying the extent of the invasive carcinoma and areas of LCIS near margins. \n * This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.\n\n\nPATHOLOGIST NAME\n\nElectronically signed: Pathologist name, Pathologist\n\n\nDiagnosis ICD code\n\nPathologist provided ICD-10:C50.412\n\n\nPath report.final diagnosis\n\nDiagnosis:A. - E. Sentinel Lymph Nodes, 1, 2, 3, 4, 5, Excisions:   Five sentinel lymph nodes negative for metastatic carcinoma.   Please see CAP summary cancer data below. \n F. Left Breast, Wire Localized Excision:   Infiltrating lobular carcinoma.   Please see Cap summary cancer data below. \n \n CAP CANCER CASE SUMMARY Invasive carcinoma of the breast: Procedure: Excision with image-guided localization. Lymph node sampling: Sentinel lymph nodes. Specimen Laterality:  Left. \n Tumor site: Upper outer quadrant, position 1 o'clock. Tumor size: 3.6 cm in maximum dimension, see comment. Histologic type: Invasive lobular carcinoma. Histologic grade: Nottingham Histologic Score Glandular/Tubular differentiation: Score 3 Nuclear Pleomorphism: Score 2 Mitotic Rate: Score 1 Overall Grade: Grade 2 Tumor focality: Single focus of invasive carcinoma. \n Ductal carcinoma in situ: No DCIS identified. Lobular carcinoma in situ: Present. \n Macroscopic and microscopic extent of tumor: Skin: Not applicable. Nipple: Not applicable. Skeletal muscle: Not applicable. \n Margins: Margin positive for invasive carcinoma. Inferior margin: Positive, two foci spanning 2 mm and 1 mm, respectively. Anterior: 2 mm Posterior: greater than 10 mm Superior: 2 mm Medial: greater than 10 mm Lateral: 3 mm. \n Ductal carcinoma in situ: DCIS not present. Lymph/vascular invasion: not identified. Dermal lymph-vascular invasion: not identified. \n Lymph nodes Total number of lymph nodes examined: 5 Number of sentinel lymph nodes examined: 5 Lymph Node Involvement: 0  Number of lymph nodes with macrometastases: 0  Number of lymph nodes with micrometastases: 0  Number of lymph nodes with isolated tumor cells: 0 Method of Evaluation of Sentinel Lymph Nodes: HE, 1 level and   immunohistochemistry. \n Lymph-Vascular Invasion: Not identified. \n Pathologic staging: AJCC, 7th ed., 2010 Primary tumor: pT2 Regional lymph nodes: pN0(i-)(sn) \n Additional pathologic findings: Biopsy site changes are present. Microcalcifications: present in nonneoplastic tissue. \n Ancillary studies: Biomarkers Performed Previously:CellNetix S17-62276(per report) Estrogen Receptor (ER) Status: 100%, moderate. Progesterone Receptor (PgR) Status: 100, strong. HER2 (by immunohistochemistry): Negative, Score 1+. \n BFI/07/31/2017 **********************************************************************\n\n\nPath report.site of origin\n\nMaterial submitted: PART A: SN #1 L PART B: SN #2 L PART C: SN #4 L PART D: SN #4 L PART E: SN #5 L PART F: BREAST TISSUE\n\n\nPath report.comments\n\nComment:The final size is calculated based on the carcinoma involving 12 contiguous slices approximately 0.3 cm thick for a total of 3.6 cm in maximum dimension, which correlates with the 3.7 cm area of abnormal enhancement seen by radiology. The largest contiguous dimension on a single slide is 1.8 cm. \n Gross evaluation of lobular carcinoma is difficult as the infiltrating cells are widely dispersed and the tissue does not always look or feel grossly abnormal. The intraoperative gross consult and final diagnosis are not discrepant.\n\n\n"
}